ClinicalTrials.gg

Program

PF-08656795

A development code.

In Pfizer's pipeline, GLP-1 receptor agonist. Its studies are mostly in Obesity, led by Pfizer.

Furthest: phase 1, since Oct 9, 20261 company-led study, 1 open or runningNext primary completion: Nov 16, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer11 open or runningphase 1since Oct 9, 2026Oct 9, 2026Nov 16, 2028phase 1 · NCT07876518
  • Named in Pfizer’s own pipeline as PF-08656795, phase 1, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 9, 2026First study: phase 1 study in OverweightFirst studyNCT07876518 · 150 planned

Ahead

  1. Nov 16, 2028Primary completion: phase 1 study in OverweightNCT07876518

TargetBeta

“GLP-1 receptor agonist”the company's pipeline, read by Claude · source

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07876518Overweight1Not yet recruitingNov 16, 2028150

How it is read

Names in the registry

  • “PF-08656795”, 1 entry

Codes read as this program: PF08656795.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.